Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

BACKGROUND: No trials have compared cabozantinib and regorafenib for the second-line treatment of advanced hepatocellular carcinoma (HCC). OBJECTIVES: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of second-line cabozantinib and regorafenib in patients with advanc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Adv Ther
Hlavní autoři: Kelley, Robin K., Mollon, Patrick, Blanc, Jean-Frédéric, Daniele, Bruno, Yau, Thomas, Cheng, Ann-Lii, Valcheva, Velichka, Marteau, Florence, Guerra, Ines, Abou-Alfa, Ghassan K.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467441/
https://ncbi.nlm.nih.gov/pubmed/32424805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01378-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky